Drug Trial Radar · NCT03099603
A Study of HTD1801 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 24, 2017
Primary completion
Jul 11, 2017
Study completion Oct 3, 2017
Sponsor
- Lead sponsor
- HighTide Therapeutics (Hong Kong) LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.
Conditions
- Primary Sclerosing Cholangitis
Interventions
HTD1801Drug
A small molecular compound for the treatment of primary sclerosing cholangitis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single doseTime frame: up to Day 30
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Limited
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.